Intellicell Biosciences Net income (FY, 2013)-11.1 M
Intellicell Biosciences EBIT (FY, 2013)-5.5 M

Intellicell Biosciences Income Statement

Annual

USDFY, 2013

Sales and marketing expense

39.6k

R&D expense

441.9k

General and administrative expense

3.7m

Operating expense total

4.1m

EBIT

(5.5m)

Interest expense

389.9k

Pre tax profit

(11.1m)

Net Income

(11.1m)

Intellicell Biosciences Balance Sheet

Annual

USDFY, 2013

Current Assets

9.0k

Total Assets

3.2m

Accounts Payable

2.6m

Short-term debt

341.1k

Long-term debt

341.1k

Total Debt

682.2k

Preferred Stock

151.0

Additional Paid-in Capital

39.0m

Retained Earnings

(48.9m)

Total Equity

(9.8m)

Debt to Equity Ratio

-0.1 x

Debt to Assets Ratio

0.2 x

Financial Leverage

-0.3 x

Intellicell Biosciences Cash Flow

Annual

USDFY, 2013

Net Income

(11.1m)

Depreciation and Amortization

405.7k

Accounts Payable

1.6m

Cash From Operating Activities

(1.2m)

Purchases of PP&E

(279.2k)

Cash From Financing Activities

930.3k

Intellicell Biosciences Ratios

USDY, 2013

Debt/Equity

-0.1 x

Debt/Assets

0.2 x

Financial Leverage

-0.3 x